Navigation Links
In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response

Telaprevir in Combination with a Long-Acting Interferon and Ribavirin Will Earn Decision Resources' Clinical Gold Standard for Hepatitis C Virus in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., March 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists and hepatologists identify a therapy's effect on sustained virologic response in genotype 1 patients as the attribute that most influences their prescribing decisions in hepatitis C virus infection. Clinical data and the opinions of interviewed thought leaders indicate that the addition of Vertex/Janssen Pharmaceutica/Mitsubishi Tanabe's telaprevir or Schering-Plough's boceprevir to peginterferon/ribavirin provide advantages in this attribute over Roche's Pegasys (peginterferon-a-2a) plus ribavirin, the sales-leading treatment in the market.

The new report entitled Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment finds that a novel protease inhibitor that, when used in combination with peginterferon/ribavirin and achieves a significantly higher sustained virologic response in genotype 1 patients with only 24 weeks of treatment compared with the standard 48-week therapy with peginterferon/ribavirin, would earn a higher patient share in the United States than in Europe. The report finds that such an agent would earn a 60 percent patient share in the U.S. and a 40 percent patient share in Europe, according to surveyed U.S. and European gastroenterologists and hepatologists.

In 2008, Decision Resources' proprietary clinical gold standard for hepatitis C virus was Pegasys plus ribavirin because of its advantages in delivery and dosing. Based on available data and expert opinion, telaprevir plus ribavirin and a long-acting interferon will earn gold-standard status for hepatitis C virus following approval of telaprevir in 2011.

"New regimens that include a protease inhibitor, such as telaprevir or boceprevir, appear to have a competitive advantage in efficacy in patients infected with genotype 1 over the current peginterferon/ribavirin regimens," said Decision Resources Vice President John Lebbos, M.D. "Furthermore, the duration of therapy for genotype 1 patients can potentially be reduced with new three-drug regimens."

About the Report

Hepatitis C Virus: Protease and Polymerase Inhibitors on the Horizon to Revolutionize Treatment is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563        

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Is telmisartan effective in treating non-alcoholic steatohepatitis?
2. Varicella zoster infection causes severe autoimmune hepatitis
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Liver transplant recipients with hepatitis B may need lifelong antiviral treatment
5. Pitt receives $11 million from NIH to coordinate hepatitis B clinical research network
6. PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine
7. Hispanics Respond Poorly to Standard Hepatitis C Therapy
8. May hepatic granulomas be part of the histological spectrum of chronic hepatitis C?
9. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
10. Hepatitis C treatment reduces the virus but liver damage continues
11. Improved Testing for Hepatitis B Virus From Roche
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... Live Very Well is excited to announce ... . The multi-carrier insurance exchange platform offers individual vision and dental ... compare, quote and match plans to meet their needs. , Beginning December ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
(Date:11/30/2015)... ... 30, 2015 , ... Stress, anxiety, illness, infection or even a need for ... , Heather Spader, MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in ... to tumors. , “Bad headaches that don’t go away, that don’t have ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... ... 30, 2015 , ... MOSI recently added two state-of-the-art augmented reality (AR) experiences ... Jurassic to their collection of interactive exhibits within the Kids In Charge! building. In ... guests to get closer than ever to a range of animals as they drink, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015   Royal Philips (NYSE: ... industry,s first MRI guided user interface and automatic scan ... with MR Conditional implants, such as knee and hip ... Radiological Society of North America Annual Meeting (RSNA) . ... diagnostic confidence of this growing patient population. ScanWise Implant ...
(Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
(Date:11/30/2015)... 2015 2014RestatedChange%Turnover 545,575 , 518,852 , 5.2 Cord Blood ... , 9.8 Hospital Management Service Income , ... Medical Insurance Administration Service Income , 2,780 , ... , 89,645 , 94,580 , ... 2,917 , (3.3) Gross Profit 395,857 , ...
Breaking Medicine Technology: